Thymoquinone in autoimmune diseases: Therapeutic potential and molecular mechanisms.

  title={Thymoquinone in autoimmune diseases: Therapeutic potential and molecular mechanisms.},
  author={Md. Yousuf Ali and Zakia Akter and Zhiqiang Mei and Meiling Zheng and Mousumi Tania and Md. Asaduzzaman Khan},
  journal={Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie},
  • M. Ali, Zakia Akter, M. Khan
  • Published 25 December 2020
  • Biology, Medicine, Chemistry
  • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Thymoquinone: Review of Its Potential in the Treatment of Neurological Diseases

Thymoquinone (TQ) possesses anticonvulsant, antianxiety, antidepressant, and antipsychotic properties. It could be utilized to treat drug misuse or dependence, and those with memory and cognitive

Berbamine and thymoquinone exert protective effects against immune-mediated liver injury via NF-κB dependent pathway

Both BE and TQ prominently attenuated ConA immune-mediated liver injury and give a remarkable insight into developing a new therapeutic agent for treating hepatitis and other autoimmune diseases.

Thymoquinone upregulates IL17RD in controlling the growth and metastasis of triple negative breast cancer cells in vitro

The data suggest that IL17RD might be epigenetically upregulated in TNBC cell lines by TQ, and this might be one of the mechanisms by which TQ exerts its anticancer and antimetastatic effects on TNBC cells.

Therapeutic Potential of Thymoquinone and Its Nanoformulations in Pulmonary Injury: A Comprehensive Review

It is concluded that TQ nanoparticles with anti-inflammatory, antioxidant, antiasthma, and antitumor activity may be safely applied to treat lung disorders.



The Role of Interleukin-17A in Psoriatic Disease

Clinical trials investigating IL-17 inhibitors, such as secukinumab, in patients with psoriatic disease have reported no significant safety concerns so far, and it is hoped that these agents will improve the long-term prognosis of patients with these debilitating disorders.

Polyphenols in the treatment of autoimmune diseases.

Targeting inflammatory mediators: An anticancer mechanism of thymoquinone action.

The role of inflammation on cancer development, and the action of thymoquinone on inflammatory molecules, which have been proved in vitro and in vivo are reviewed.

The Immunomodulatory and Anti-Inflammatory Role of Polyphenols

It is shown that polyphenols can play a beneficial role in the prevention and the progress of chronic diseases related to inflammation such as diabetes, obesity, neurodegeneration, cancers, and cardiovascular diseases, among other conditions.

Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics

The introduction of anti-TNF therapeutics has revolutionized the management of autoimmune diseases, such as RA, psoriatic arthritis (PsA), plaque psoriasis (PP), AS, CD and ulcerative colitis (UC), and may represent a safer and more effective treatment, as proposed by some recent studies.

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

The JAK–STAT pathway is described, its role in autoimmunity is outlined, and the rationale/pre-clinical evidence for targeting JAK-STAT signaling is explained, starting with the FDA-approved Jakinib tofacitinib, and continuing on to next-generation JakinIBs.

NLRP3: A promising therapeutic target for autoimmune diseases.

[Tumor necrosis factor alpha (TNF-α) in autoimmune diseases (AIDs): molecular biology and genetics].

The biological role of TNF-α under normal conditions and the initiation, development, susceptibility, severity, and treatment response of the most common AIDs are presented.

Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis

The fact that TQ abolishes a number of factors known to be involved in RA pathogenesis renders it a clinically valuable agent in the prevention of articular diseases, including RA.

The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis

Treatment with TNF-α, by destroying autoreactive T cells, appears to be a highly targeted strategy to interrupt the pathogenesis of type 1 diabetes, lupus and certain forms of autoimmunity.